Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma

Experimental Hematology
N KrögerB Fehse

Abstract

To investigate lineage-specific chimerism of plasma cells after allogeneic transplantation by real-time PCR based on bi-allelic sequence polymorphism or, in case of female-to-male transplantation, on the detection of the DFFRY gene and to determine its value to quantify minimal residual disease in myeloma patients. Forty-eight samples from bone marrow samples and peripheral blood from 34 nonmyeloma patients were analyzed at different times after transplantation. Sixty-two samples from 22 myeloma patients were analyzed at different times after allogeneic stem cell transplantation, and results were compared with immunofixation and, in some cases, with PCR data using patient-specific primers. The median chimerism for T cells at day +100 was greater than 99.9% and remained stable on day +180 and 1 year after transplantation. In contrast, the median donor plasma cell chimerism at day +100 was 95.5%, at day +180 98.6%, at day +360 99.8%, and 2 or more years after transplantation greater than 99.9%. Sensitivity of real-time PCR using human short insertion/deletion polymorphisms (SIDP) was 10(-4) and in case of Y-PCR 10(-5). Sequential monitoring of donor plasma cell chimerism showed that increasing and stable chimerism were associated...Continue Reading

References

May 10, 2003·Blood·Paolo CorradiniUNKNOWN Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Mar 18, 2005·Annual Review of Immunology·Rudolf A ManzAndreas Radbruch
Apr 29, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Melissa AlsinaUNKNOWN Resource for Clinical Investigation in Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

Dec 5, 2013·International Journal of Hematologic Oncology·Lindsay Am ReinDavid A Rizzieri
Jul 28, 2012·Stem Cell Reviews and Reports·S Abdul Wahid Fadilah, Md Pazil Aqilah
Feb 28, 2007·Leukemia & Lymphoma·Guillermo J Ruiz-ArgüellesJavier Garcés-Eisele
Jan 29, 2011·Expert Opinion on Biological Therapy·Claire Roddie, Karl S Peggs
Apr 24, 2007·Best Practice & Research. Clinical Haematology·F Dazzi, C Fozza
Mar 22, 2015·Experimental Hematology·Tanja StahlBoris Fehse
Nov 5, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerMichael R Bishop
Oct 20, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerAxel R Zander
Sep 4, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leo RascheStefan Knop
May 10, 2019·Expert Review of Clinical Immunology·Reem ElfekyPaul Veys
Apr 30, 2019·Frontiers in Immunology·Nicolaas G van der MaasArjan C Lankester
Apr 22, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C AndersonElena Zamagni
Apr 13, 2021·British Journal of Haematology·Thomas LongvalFlore Sicre de Fontbrune
Jan 28, 2022·Bone Marrow Transplantation·Amanda G Blouin, Medhat Askar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.